Podcast

Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer

Author(s):

Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

Welcome to OncLive On Air®! I’m your host today, Jason Harris.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, I spoke with Philippe Spiess, MD, about penile cancer for our Rare Cancers series. Dr Spiess is a genitourinary oncologist and the assistant chief of surgical services at the Moffitt Cancer Center, and full professor of oncology and urology at the University of South Florida Morsani College of Medicine.

Penile is extremely rare in North America. The American Cancer Society estimates there will be 2070 new diagnoses and 470 deaths from the disease in 2022.

Penile cancer is curable if caught early but, for a variety of reasons including lack of familiarity with the conditions, many patients present with advanced disease. Moreover, there is a lack of systemic treatments available and surgery is often described as “mutilating.” Because the disease is so rare, there is a lack of clinical research and, as a result, treatment hasn’t advanced in a decade.

In our interview, Dr Spiess talked about taking part of an international consortium that seeks to establish standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, and thanks again to my guest, Dr Philippe Spiess. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Chad Tang, MD
Martin H. Voss, MD
Martin H. Voss, MD
Alexandra Drakaki, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Alexandra Drakaki, MD, PhD
Adam E. Singer, MD, PhD
Chad Tang MD, MD Anderson